Last $54.56 USD
Change Today -1.22 / -2.19%
Volume 959.7K
As of 8:04 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

quintiles transnational hold (Q) Snapshot

Open
$56.26
Previous Close
$55.78
Day High
$56.50
Day Low
$54.08
52 Week High
09/11/14 - $58.89
52 Week Low
10/31/13 - $40.10
Market Cap
6.9B
Average Volume 10 Days
597.4K
EPS TTM
$2.48
Shares Outstanding
127.3M
EX-Date
--
P/E TM
22.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for QUINTILES TRANSNATIONAL HOLD (Q)

quintiles transnational hold (Q) Related Businessweek News

No Related Businessweek News Found

quintiles transnational hold (Q) Details

Quintiles Transnational Holdings Inc., through its subsidiary, Quintiles Transnational Corp., provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia-Pacific. The company operates through two segments, Product Development and Integrated Healthcare Services. The Product Development segment provides project management and clinical monitoring services, including study design and operational planning, investigator/site recruitment, site and regulatory start up, patient recruitment, clinical monitoring, and project management for conducting various multi-site trials; and clinical trial support services comprising clinical data management, biostatistical, central laboratories, genomic laboratory, bioanalytical laboratories, cardiac safety and ECG, safety and pharmacovigilance, and phase I clinical pharmacology services. It also provides strategic planning and design services; and consulting services, such as product development strategy, regulatory and compliance, and process and IT implementation consulting services. The Integrated Healthcare Services segment offers commercial services comprising contract sales, market entry/market exit, integrated channel management, patient engagement, market access and commercialization consulting, and medical education services; communication and health engagement services, including digital patient, and brand and scientific communications services; and outcome-based services, such as observational studies, comparative effectiveness studies, and product and disease registry services. The company serves biopharmaceutical companies, including medical device and diagnostics companies. Quintiles Transnational Holdings Inc. was founded in 1982 and is based in Durham, North Carolina.

30,700 Employees
Last Reported Date: 07/31/14
Founded in 1982

quintiles transnational hold (Q) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.0M
Executive Chairman
Total Annual Compensation: $871.2K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.1M
Chief Customer & Governance Officer and Execu...
Total Annual Compensation: $838.4K
Consultant
Total Annual Compensation: $526.3K
Compensation as of Fiscal Year 2013.

quintiles transnational hold (Q) Key Developments

Quintiles Launches New Customer Solution to Meet the Unique Needs of Emerging Biopharmaceutical Companies

Quintiles expanded its solution set with the launch of the Quintiles Emerging Biopharma Solution -- a new offering designed to meet the unique clinical development needs and goals of these companies. The Quintiles Emerging Biopharma Solution is a newly developed operating model that is aligned with customer needs within this segment and leverages Quintiles' integrated technology platforms to provide customers with real-time data access as well as a transparent view of project performance. In addition to providing a dedicated leader with emerging biopharmaceutical operations expertise, the offering includes senior-level sponsorship for each customer. This level of support provides easy access to the unique expertise and nimble operational support required by these companies. The new offering covers all therapeutic areas and adds to the proven oncology expertise of Novella Clinical -- Quintiles' oncology service provider for emerging biopharmaceutical customers that possesses unique experience serving these companies. Recognized once again this year as an industry leader in Phase I and Phase II/III research among small biopharmaceutical customers, Quintiles has applied its proven experience in working with these companies to address their specific needs in areas such as start-up, patient recruitment and trial execution as part of this new offering.

Quintiles Transnational Holdings Inc. - Analyst/Investor Day

Quintiles Transnational Holdings Inc. - Analyst/Investor Day

Quintiles Transnational Holdings Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 09:55 AM

Quintiles Transnational Holdings Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 09:55 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Thomas H. Pike, Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
Q:US $54.56 USD -1.22

Q Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioanalytical Systems Inc $2.23 USD -0.08
View Industry Companies
 

Industry Analysis

Q

Industry Average

Valuation Q Industry Range
Price/Earnings 23.5x
Price/Sales 1.8x
Price/Book NM Not Meaningful
Price/Cash Flow 22.5x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUINTILES TRANSNATIONAL HOLD, please visit www.quintiles.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.